SU1120923A3 - Способ получени 6,7-дихлор-1,5-дигидроимидазо (2,1- @ )хиназолин 2(3 @ )-она - Google Patents

Способ получени 6,7-дихлор-1,5-дигидроимидазо (2,1- @ )хиназолин 2(3 @ )-она Download PDF

Info

Publication number
SU1120923A3
SU1120923A3 SU792751007A SU2751007A SU1120923A3 SU 1120923 A3 SU1120923 A3 SU 1120923A3 SU 792751007 A SU792751007 A SU 792751007A SU 2751007 A SU2751007 A SU 2751007A SU 1120923 A3 SU1120923 A3 SU 1120923A3
Authority
SU
USSR - Soviet Union
Prior art keywords
dichloro
dihydroimidazo
quinazoline
obtaining
formula
Prior art date
Application number
SU792751007A
Other languages
English (en)
Inventor
Эндрю Дженкс Томас
Нейл Биверунг Уоррен (Младший)
Энтони Партика Ричард
Original Assignee
Бристоль Мейерз Компани (Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристоль Мейерз Компани (Фирма) filed Critical Бристоль Мейерз Компани (Фирма)
Application granted granted Critical
Publication of SU1120923A3 publication Critical patent/SU1120923A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/12—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

СПОСОБ ПОЛУЧЕНИЯ 6 7-ДИХЛОР-1 ,5-ДИГИДРОИМИДАЗО

Description

31
Смесь, содержащую бромистоводородного этид-5,6-дихлор-дигидро-2 (1Н)-иминохиназолин-3-ацетата 6 г (0,043 моль), абсолютного этанола (2,8 мл и триэтиламина 0,66 мл (0,004 моль), нагревают с обратным холодильником в течение 4 ч. Смесь охлаждают и удал ют декантацией как можно больше этанола. Затем твердое вещество суспендируют в свежеприготовленном абсолютном этаноле и после перемешивани  смеси в течение 0,5 ч, фильтруют. После этого твердое вещество суспендируют в смеси абсолютного этанола (3,8 мл) и 95% этанола (15 мл) и нагревают с обратным холодильником в течение 4 ч. Теплую смесь фильтруют. Твердое вещество сущат. в вакууме (0,5-1 мм рт.ст.) над фосфорным ангидридом. Получают 1,45 г (92%) указанного продукта в
09234
виде твердого вещества цвета слоновой кости.
ИК-пики: 1702 (слабо), 1638, 1554, 1468 и 1440
5ЯМР-пики (ТФА): S 7,33 (АВ, q,.2H)
4,97 (S, 2Н) и 4,59 (S, 2Н).
Соединени  формулы III имеют одну структурную формулу, однако соединение формулы III может существовать 10 также в таутомерной форме Ilia:
N.,,NH-HBr
Т . о
N II
dHgdodgHs
Причем обе таутомерные формы,т.е. 20 III и Ilia, при обработке основанием да1Ьт требуемый продукт формулы 1.

Claims (2)

  1. СПОСОБ ПОЛУЧЕНИЯ 6,7-ДИХЛОР-1,5-ДИГИДРОИМИДАЗО (2,1-Ъ) ХИНАЗОЛИН
  2. 2(ЗН)-0НА ФОРМУЛЫ ,
    Cl включающий взаимодействие соединения формулы с бромцианом в .кн2 z о ‘СН2ЛНСН2С0СгН5 органическом раство рителе, отличающийся тем, что, с целью повышения выхода целевого продукта, в качестве органического растворителя используют толуол и полученное соединение формулы w NH-HBr
    Υ θ
    Л ΑΛΑ II
    Ct γ Сн2Сос2н5
    Cl подвергают взаимодействию с эквимолярным количеством органического основания, например триэтиламина, в среде этилового спирта при нагрева нии. до температуры дефлегмации растворителя.
    SU ,,,, 1120923 t 1
SU792751007A 1978-04-10 1979-04-09 Способ получени 6,7-дихлор-1,5-дигидроимидазо (2,1- @ )хиназолин 2(3 @ )-она SU1120923A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/894,464 US4146718A (en) 1978-04-10 1978-04-10 Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides

Publications (1)

Publication Number Publication Date
SU1120923A3 true SU1120923A3 (ru) 1984-10-23

Family

ID=25403115

Family Applications (1)

Application Number Title Priority Date Filing Date
SU792751007A SU1120923A3 (ru) 1978-04-10 1979-04-09 Способ получени 6,7-дихлор-1,5-дигидроимидазо (2,1- @ )хиназолин 2(3 @ )-она

Country Status (19)

Country Link
US (1) US4146718A (ru)
JP (2) JPS54135794A (ru)
AU (1) AU527748B2 (ru)
BE (1) BE875475A (ru)
CA (1) CA1109067A (ru)
CH (1) CH639079A5 (ru)
DE (1) DE2914494A1 (ru)
DK (1) DK156062C (ru)
FI (1) FI66616C (ru)
FR (1) FR2422649A1 (ru)
GB (1) GB2018765B (ru)
GR (1) GR72937B (ru)
HU (2) HU179424B (ru)
IE (1) IE48150B1 (ru)
NL (1) NL191182C (ru)
SE (2) SE445217B (ru)
SU (1) SU1120923A3 (ru)
YU (1) YU40554B (ru)
ZA (1) ZA791727B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2298007C2 (ru) * 2001-10-15 2007-04-27 Е.И.Дюпон Де Немур Энд Компани Соединение, композиция для борьбы с насекомыми, способы борьбы с насекомыми

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1131631A (en) * 1979-06-20 1982-09-14 Madhukar S. Chodnekar Quinazoline derivatives and pharmaceutical preparations
US4818273A (en) * 1983-11-14 1989-04-04 The Dow Chemical Company Substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides, compositions containing them, and their utility as herbicides
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) * 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
JPH05271200A (ja) * 1991-05-22 1993-10-19 Egyt Gyogyszervegyeszeti Gyar ６，７−ジクロロ−１，５−ジヒドロ−イミダゾ〔２，１−ｂ〕キナゾリン−２〔３Ｈ〕−オンの製造方法
US5391737A (en) * 1991-05-22 1995-02-21 Egis Gyogyszergyar Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6585995B1 (en) 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
US6194420B1 (en) * 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6388073B1 (en) * 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
DE10301105B4 (de) * 2003-01-09 2005-11-24 Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation
HRP20050633A2 (en) * 2003-01-23 2006-06-30 Shire Holdings Ag Formulation and methods for the treatment of thrombocythemia
AT412873B (de) * 2004-02-20 2005-08-25 Aop Orphan Pharmaceuticals Ag Verfahren zur herstellung von anagrelid hydrochlorid
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
GB0623749D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
JP2010518060A (ja) * 2007-02-06 2010-05-27 シプラ・リミテッド エチル−ｎ−（２，３−ジクロロ−６−ニトロベンジル）グリシン塩酸塩の製造方法
CN101463035A (zh) * 2007-12-19 2009-06-24 华生制药私人有限公司 生产盐酸阿那格雷一水合物的改进方法
GB0808951D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808944D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808953D0 (en) * 2008-05-16 2008-06-25 Shire Llc substituted quinazolines
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB201004491D0 (en) 2010-03-18 2010-05-05 Shire Llc Quinazoline analogues
GB201017783D0 (en) 2010-10-21 2010-12-01 Shire Llc Process for the preparation of anagrelide and analogues thereof
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
ES2794917T3 (es) * 2013-01-18 2020-11-19 Synthon Bv Forma cristalina II de clorhidrato de anagrelida monohidratado
EP2981537B1 (en) * 2013-03-14 2017-05-10 Synthon B.V. Process for making anagrelide
WO2014206484A1 (en) 2013-06-28 2014-12-31 Synthon B.V. Process for making anagrelide
CN106854162A (zh) * 2016-12-13 2017-06-16 浙江海正化工股份有限公司 一种2,3‑二氯‑6‑硝基苯胺及其制备方法
CN107903217B (zh) * 2017-11-16 2021-11-23 湖北省宏源药业科技股份有限公司 一种阿那格雷杂质b的制备方法
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
BE794964A (fr) * 1972-02-04 1973-08-02 Bristol Myers Co Nouveaux agents hypotenseurs et procede pour les preparer
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1. Патент US № 3932407, кл. 260-239, опублик. 1975 (прототип) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2298007C2 (ru) * 2001-10-15 2007-04-27 Е.И.Дюпон Де Немур Энд Компани Соединение, композиция для борьбы с насекомыми, способы борьбы с насекомыми

Also Published As

Publication number Publication date
NL191182B (nl) 1994-10-03
ZA791727B (en) 1980-05-28
GB2018765A (en) 1979-10-24
SE8404061D0 (sv) 1984-08-10
JPH0233035B2 (ru) 1990-07-25
YU83079A (en) 1983-12-31
CA1109067A (en) 1981-09-15
DE2914494A1 (de) 1979-10-18
NL191182C (nl) 1995-03-01
FR2422649B1 (ru) 1983-07-29
DE2914494C2 (ru) 1989-07-20
JPH0312066B2 (ru) 1991-02-19
FR2422649A1 (fr) 1979-11-09
AU527748B2 (en) 1983-03-24
SE445217B (sv) 1986-06-09
GR72937B (ru) 1984-01-13
BE875475A (fr) 1979-10-10
FI66616B (fi) 1984-07-31
AU4588979A (en) 1979-10-18
DK156062B (da) 1989-06-19
IE790753L (en) 1979-10-10
US4146718A (en) 1979-03-27
DK156062C (da) 1989-11-06
SE8404061L (sv) 1984-08-10
JPH0222276A (ja) 1990-01-25
CH639079A5 (de) 1983-10-31
HU187562B (en) 1986-01-28
DK144779A (da) 1979-10-11
SE454990B (sv) 1988-06-13
GB2018765B (en) 1982-08-04
JPS54135794A (en) 1979-10-22
YU40554B (en) 1986-02-28
HU179424B (en) 1982-10-28
NL7902825A (nl) 1979-10-12
FI66616C (fi) 1984-11-12
FI791125A7 (fi) 1979-10-11
IE48150B1 (en) 1984-10-17
SE7903198L (sv) 1979-10-11

Similar Documents

Publication Publication Date Title
SU1120923A3 (ru) Способ получени 6,7-дихлор-1,5-дигидроимидазо (2,1- @ )хиназолин 2(3 @ )-она
US3669979A (en) Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst
US4353829A (en) Process for 5-aroylation of 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic esters
KR920002825B1 (ko) 피리미딘 유도체 및 그의 제조방법
JP2524491B2 (ja) 新規なアミノカルボン酸エステル及びその製法
KR0172965B1 (ko) 5,7-디하이드록시-1,2,4-트리아졸로[1,5-a] 피리미딘-2-설폰아닐리드의 제조방법
Igglessi‐Markopoulou et al. Acylaminoacetyl derivatives of active methylene compounds. 1. The cyclization of the benzoylaminoacetyl derivatives to α‐substituted tetramic acids
EP0017181A1 (de) Neues Verfahren zur Herstellung von Imidazobenzodiazepinderivaten sowie Zwischenprodukte zu deren Herstellung
US4041077A (en) N-benzyl-2,2-dimethoxy-acetamides
JP3317309B2 (ja) ３−置換アミノ−４，４，４−トリフルオロクロトン酸エステルの製造法
DE3005709C2 (ru)
EP0054002A1 (de) Verfahren zur Herstellung von 3-Pyrazolidinonen und ihre Verwendung in photographischen Entwicklerlösungen
DE68904395T2 (de) Verfahren zur synthese von 3-chlor-2,4,5-trifluorbenzoesaeure.
EP0119091B1 (en) 2,2-diethoxypropionic acid derivatives
SU1313856A1 (ru) Способ получени производных цис- или транс-диаминодибензоилдибензо-18-краун-6
SU415876A3 (ru) Способ получения производных бензимидазола
KR100305288B1 (ko) 2-아릴-5-트리플루오로메틸피롤화합물의제조방법
Beall et al. 1, 3-Bisalkylcarbonyl-and 3-alkylcarbonyl-5-fluorouracil prodrugs: Syntheses, thermal, and hydrolytic stability
SE8205563L (sv) Sett att framstella vinkaminsyraestrar
SU1447825A1 (ru) Способ получени 3а-7а-дифенилтетрагидроимидазо[4,5- @ ]имидазол-2,5-диона
Li Synthesis of 1-substituted and 1, 3-disubstituted 5-hydantoincarboxylates
SU1634669A1 (ru) Способ получени 4-амино-5-тозилимидазо(1 @ ,2 @ :1,6)пиридо(2,3- @ )-пиразина
SU1299504A3 (ru) Способ получени производных 3-хлор-1-формил-4-фенилпирролов
SU340272A1 (ru) СПОСОБ ПОЛУЧЕНИЯ 2-АРИЛ-4-АЛКИЛ(АРИЛ)-5-МЕТИЛ-1,2,4- ОКСАДИАЗИНДИОНОВ-3,6Изобретение относитс к способу получени 2-арил-4 - алкил(арил)-5-метил - 1,2,4-оксадиа- зиндионов-3,6, которые вл ютс аналогами физиологически активных производных 3,6-Ди- кетопиридазинов и обладают ценным биологическим действием.Известен аналогичный способ получени 1,2,4-оксадиазиндионов-3,5, заключаюш,ийс в том, что хлорацетилхлорид реагирует своей хлорметильной грунной с N-метилкарбамоил- N-арилгидроксиламинами. Получают первичный продукт реакции, циклизаци которого в присутствии избытка основани приводит к производным 1,2,4-оксадиазиндионов-3,5.Однако при реакции с N-€2—Сз-алкилкарба- моильными производными хлорацетилхлорид действует как ацилирующее средство, а образующиес при реакции о-хлорацетил-Ы-алкил- карбамоил-Ы-арилгидроксил амины гидролитически очень нестойки и при разложении дают исходные Ы-алкилкарбамоил-М-арилгидро- ксиламины.Предлагаемый способ состоит в том, что дл получени 2-арил-4-алкил(арил)-5-метил-1,2,4-оксадиазиндиомоЁ-3,6 общей формулы10где X- пводород, галоид, алкиЛ; 1 или 2; R — водород, алкил(арил),15 проводитс реакци М-алкил(арил)карбамоил- N-арилгидроксиламинов с галоидаигидридами а-галоиднропионовых кислот в присутствии 2 моль основани . Реакцию можно проводить в одну стадию или с выделением промежуточ- 20 ио образующихс о-а-галоиДпропионил-'Н-ал- кил{арил)карбам.оил - N - арилгидроксиЛами- нов. В последнем случае эквимол риые количества основани ввод т раздельно по стади м
SU462830A1 (ru) Способ получени фосфорсодержащих 1-фенил-5-метилтриазолов-1,2,3